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Abstract
Background: Migraine headache prevalence and triggers in type2 diabetes mellitus (T2DM) were investigated in
previous studies but the results are contradictory. Therefore, in this study we examined the prevalence of migraine
headache in diabetic patients in comparison with non-diabetic persons and its predisposing factors in 2014.
Methods: We enrolled 147 volunteer patients with T2DM and 150 healthy persons referred to the Yazd Diabetes
Research Center and the Central Laboratory of Yazd, respectively, in 2014. The data collection instrument was a
self-conducted checklist. The checklist contained demographic, anthropometric and clinical characteristics and
migraine diagnostic questions according to International Classification of Headache Disorders Second Edition
(ICHD-II) criteria. We compared prevalence of migraine between two groups, and also evaluated relationship
between above characteristics and migraine prevalence in both groups.
Results: The prevalence of migraine in participants of diabetic and non-diabetic was 27.9 and 26 %, respectively
(p-value = .406). The prevalence of migraine headache among in diabetic persons was significantly correlated with
family history of migraine, diabetes duration and hypoglycemia attacks. Also, the migraine prevalence was
significant more prevalent in T2DM patients with duration 6–10 years (p-value = 0.031). The percentage of HbA1C,
type of anti-diabetic medication, BMI value and age in diabetic patients did not show any significant association
with migraine.
Conclusion: Although we observed no significant differences in prevalence of migraine between patients with
T2DM and non-diabetic age and sex adjusted persons But, the occurrence of hypoglycemia attacks and T2DM
duration were related to migraine prevalence. Decreasing hypoglycemia among long-time T2DM patients probably
can decline migraine headache in this group of patients.
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Background
Type2 diabetes mellitus (T2DM) influences all ages, and
its prevalence is increasing worldwide [1]. This disease is
correlated with an enhanced risk of several other chronic
disorders [2] and causes multitude complications such
as diabetic neuropathy, retinopathy and cardiovascular
disorders. Among the complications related to diabetes
mellitus, association between migraine and diabetes is
controversial. Migraine is a neurovascular disorder with
complex pathophysiology and recurrent headache attacks.
Duration of migraine headache is 4 to 72 h and is usually
accompanied by nausea, vomiting, or sensibility to sound,
light, or motion [3, 4]. Migraine associated with an exten-
sive range of subtypes, multiple co-morbidities and a
changeable prognosis and has been better investigated
than other type of headaches [5]. A World Health
Organization (WHO) review of universal data detected
migraine to be one of the most common health diseases
worldwide, and the most prevalent reason of headache
consultation in America, South-East Asia, Europe, and the
Western Pacific [6]. The reason of migraine is unknown
[7] and several researches have shown that genetics and
environmental factors are significant pathophysiologic
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causes of migraine [8]. Since migraine is a complex
disease and several factors are involved it, numerous
studies have investigated to discover its predisposing
factors. Hypoglycemia and fasting that is seen com-
monly in diabetic patients are among these factors. So,
we compared the prevalence of migraine in diabetic
and non-diabetic people and evaluated relationship
between migraine and some factors including age, sex,
hypoglycemia induced by anti-diabetic drug, glycosylated
hemoglobin (HbA1c), family history, educational level
and job in diabetic and non-diabetic individuals in Yazd
Diabetes Research Center in 2014.
Methods
An HbA1C of 6.5 % is recommended as the cut of
point for diagnosing diabetes. In this study, was used
Japanese toso device and HPLC (High Performance Liquid
Chromatography) technique to measure HbA1C levels.
This cross-sectional study was carried out in type 2 dia-
betic patients referred to Yazd Diabetes Research Center
in 2014. Sample size was calculated with sample size
calculation formula for limited population. The study
sample was 147 diabetic patients that were randomly
selected among 10000 diabetic patients between 30 and
45 years-old referred to Yazd Diabetes Research Center
in 2014. One hundred and fifty age and sex matched
non-diabetic people were randomly selected from the
Central Laboratory of Yazd. The exclusion criteria were
patients with hypertension [4]. The samples were re-
cruited in 2014. The data collection instrument was a self-
conducted checklist. The checklist contained demographic
information (sex, age, employment, education, family
history of migraine in first degree relatives, history of
hypoglycemia, duration of T2DM and anti-diabetic medi-
cations), anthropometric measurement (Body Mass Index
value), Laboratory findings (Fasting Plasma Glucose, Post
prandial plasma glucose and HbA1c tests) and migraine
diagnostic questions according to International Classifica-
tion of Headache Disorders Second Edition (ICHD-II) cri-
teria. The universally accepted international classification
of headache disorders, first published in 1988, has now
been replaced by a second edition ICDH-2. It is important
to implement the new edition immediately since there are
many important changes compared with the first edition.
Application of the new edition is the only way to assure
that the same diagnostic approach and appropriate treat-
ment are provided for all headache patients. The ICHD-II
criteria for diagnosis of migraine are; The duration of no-
remedy or failed treated episodes ranges from 4 to 72 h.
The headaches are determined with containing at least
two subsequent pain characteristics: unilateral status,
pulsating state, moderate or severe intensity, Inability to
perform physical activity. The headache is accompanied
by at least one of the following signs: nausea or vomiting,
photophobia, and sensitivity to sound. Also, the patient
must have a history of at least five prior attacks according
to the diagnostic criteria [7]. Weight and height of partici-
pants were measured by researcher, and BMI was calcu-
lated by dividing weight in kilograms by height in square
meters. The BMI values ≤20 kg/m2, 20–25 kg/m2, ≥25 kg/
m2 and ≥30 kg/m2, respectively, defined as underweight,
normal weight, overweight and obese [9]. The sample size
was calculated by comparison of two prevalences. The
power of study was 85 %, α was 0.05 and the differences
between groups was 0.2.
The data obtained using descriptive statistics and
inferential statistics (chi-square test) and analysis was
done using SPSS software 20. P-value of < .05 was con-
sidered as statistically significant.
This study is adopted in Ethics Committee of Yazd
Diabetes Research Center, based on the Helsinki
Declaration.
Results
The prevalence of migraine in diabetics and non-diabetics
were 27.9 and 26 %, respectively (P-value = .406)
(Table 1) . The prevalence of migraine in diabetic pa-
tients with a family history of migraine in first degree
relatives and without the history was 50 and 20.9 %,
respectively (p-value > 0.001), and the prevalence of mi-
graine in diabetic persons with a history of hypoglycemia
and without the history was 41.2 and 16.7 %, respectively
(p-value > 0.001). Duration of diabetes was significantly
associated with migraine prevalence (p-value = .031)
(Fig. 1). The migraine prevalence in patients treated with
insulin, oral anti-diabetic agents and no medication were
27.9, 29.5 and 23.1 %, respectively (p-value = 0.549) (Fig. 2).
Also, no significant difference was found in the prevalence
of migraine in diabetic patients with high levels of HbA1c
(poor control of diabetics) (Fig. 3). Also, the age and BMI
in diabetics and non-diabetics indicated no significant
correlation with migraine prevalence (Figs. 4 and 5). The
complementary comparisons between two groups were
described in Table 2.
Discussion
We observed no significant difference in the prevalence
of migraine between patients with diabetes and non-
diabetic age and sex matched group. Also, among fac-
tors that we studied in diabetic patients, only the family
history of migraine in first degree relatives, the history
of hypoglycemia and duration of T2DM were signifi-
cantly related to migraine prevalence.
The correlation between migraine and diabetes is yet
unknown, and there are conflicting results about preva-
lence of migraine in persons with diabetes [10]. In our
study, the prevalence of migraine in diabetic and non-
diabetic participants was 27.9 and 26 %, respectively,
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and the difference of migraine prevalence between two
groups was statistically non significance (p-value = .406).
Several previous studies have been designed to investigate
the relation between migraine and diabetes [11, 12]. Some
studies illustrated lower prevalence of migraine in patients
with diabetes [13, 14], a similar [15] or higher prevalence
[12, 16] was detected in other researches. The cohort
study in 2012, found no correlation between migraine and
T2DM [13]. A study suggested that the blood glucose
level is the key and special triggering mechanism of mi-
graine in some persons; Blau et al. selected 36 patients
with both migraine and T2DM. Five patients lost their
migraine perfectly or had a considerable decrease in
their attacks with the onset or control of T2DM, and
decline frequency and intensity of migraine in remark-
able number of patients were found after developing
T2DM; but, in 21 patients, diabetes in no way impressed
migraine [17]. In addition, insulin resistance that is the
core pathophysiology of T2DM has been correlated in
some patients with migraine [18]. For example, a recent
study indicated that insulin sensitivity is impaired in
patients with migraine [5, 19], and another research
confirmed an important relation between insulin resist-
ance and migraine in sixty non-obese patients with
migraine [20].
In our study, there was no significant difference in mi-
graine prevalence between the age groups of 30–35, 36–40
and 41–45 years old in both two groups of diabetics and
non-diabetics (p-values of .471 and .251, respectively). The
previous studies indicated that highest prevalence of
migraine occurs between ages 22 to 55 years old [21].
Berge LI et al. represented a considerable decreased
prevalence of migraine among older patients with T2DM.
This preventive effect of diabetes on migraine was only
found among Patients older than 50 years old. But,
Table 1 Background characteristic of participants without and




group, n = 150
No. (%) No. (%)
Sex Male 55 (37.4) 48 (32)
Female 92 (62.6) 102 (68)
Employment No 87 (59.2) 84 (56)
Yes 60 (40.8) 66 (44)
Education Below
diploma
94 (64.8) 52 (34.7)
Diploma and
upper




No 110 (75.3) 109 (72.7)
Yes 36 (24.7) 41 (27.3)
Age (years) 30–35 13 (8.8) 61 (40.7)
36–40 26 (17.7) 44 (29.3)
41–45 108 (73.5) 45 (30)
BMI (kg/m2) 20–25 35 (24) 53 (35.3)
25–30 67 (45.9) 66 (44)




Insulin 43 (29.3) ……
Oral agants 78 (53) ……
Hypoglycemia No 78 (53.4) ……
Yes 68 (46.6) ……
HbA1c (%) 5–7 31 (21) ……
7–9 63 (42.9) ……
9–15 53 (36.1) ……
Duration of
diabetes (years)
1–5 85 (57.8) ……
6–10 30 (20.4) ……
11–15 22 (15) ……
16–20 10 (6.8) ……
Migraine No 106 (72.1) 111 (74)
Yes 41 (27.9) 39 (26)
BMI indicates body mass index, HbA1c (%), percentage of blood glycosylated
hemoglobin, No. (%) frequency of variables
Fig. 1 Migraine prevalence with p-value of 0.031 related to
T2DM duration
Fig. 2 The prevalence of migraine between diabetic patients with
diverse medications of T2DM (p-value of .549)
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prevalence of migraine in patients 40 to 49 years old
was identical with the non-diabetic group and in pa-
tients less than 40 years old was higher. These findings
suggested the presence of a potent age-related factor in
migraine occurrence [2].
In our study, the prevalence of migraine in persons
with T2DM duration of 1–5, 6–10, 11–15 years was
25.9, 33.3 and 40.9 %, respectively, and migraine preva-
lence with p-value of 0.031 related to T2DM duration.
There was no case of migraine in T2DM duration of 16–20
years. Aamodt et al. represented a reverse correlation be-
tween Duration of T2DM and migraine prevalence in
middle-aged and elderly patients for more than 13 years.
As a result of this study was conjectured that diabetes
mellitus may in some paths protect versus migraine, or
vice versa. The cause of relationship between migraine
prevalence and diabetes duration is unknown, but
might be correlated to pathophysiological abnormalities
[11]. One of these mechanisms may be a reduction of
some neurotransmitters (e.g. nitric oxide, noradrenalin,
and substance P) in nerve terminals of patients with
diabetic neuropathy that this may be associated to mi-
graine pathophysiology [20].
In our study, the prevalence of migraine in patients
with diabetes with a history of hypoglycemia was
significantly higher than patients without a history of
hypoglycemia (P-value of .001). Hypoglycemia may
accelerate headache in some patients with T2DM (and
non-diabetic persons) [22] and is one of the side effects
of anti-diabetic medication. The brain function depends
on a continuous glucose supply and is vulnerable to
any deficiency of glucose. So, the brain is one of the
first organs that affected by reduced blood glucose
levels [23]. In a study, overnight hypoglycemia acceler-
ated migraine headaches in some patients with both
migraine and T2DM. It expresses the relationship be-
tween blood glucose levels and the occurrence of mi-
graine headaches [17].
Migraine happens more prevalently in adult women
than men [24]. In the United States, one-year prevalence
of migraine is estimated 18 % in women, which is three
times more prevalent in men [25]. Also, a study in Turkey
showed the lifetime prevalence of migraine in men and
women as 7.9 % and 17.1 % [26]. The results of our re-
search confirm the findings of previous studies; a higher
prevalence of migraine in both women of diabetics and
non-diabetics groups (p-value of < .001).
In previous studies it has been suggested that mi-
graine issued from a genetic basis. People with a family
history of migraine are more susceptible to migraine.
The results of our study about two groups of diabetics
and control confirmed previous findings. Migraine is a
multifactorial disease and has a complex inheritance
[4]. Globally, migraine prevalence is highest in the
Americas and Europe and lowest in Africa and Asia .
Also, a resembling race pattern is observed in the
United States, where number of whites is more than
African- and Asian-Americans, proposing race-related
diversities in genetic vulnerability to migraine [3].
Some medicines used to treat metabolic disorders indi-
cated an important effect in prophylaxis of migraine [18].
Fig. 3 The prevalence of migraine between diabetic patients with
diverse levels of HbA1c (p-value of .306)
Fig. 5 The BMI groups had no significant difference in the prevalence
of migraine in both two group of diabetics and non-diabetics (p-values
of .712 and .492, respectively
Fig. 4 The age groups had no significant difference in the prevalence
of migraine in both two group of diabetics and non-diabetics (p-values
of .471 and .251, respectively)
Haghighi et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:37 Page 4 of 7
For example, in a study, patients using anti-diabetic medi-
cations had an overall decreased prevalence of medically
treated migraine compared with the non-diabetic persons.
Although young patients taking oral anti-diabetic
agents had an elevated prevalence of medically treated
migraine, the prevalence decreased with increasing age
to about the identical reduced prevalence for all kinds
of T2DM treatment in Patients 60–90 years old [2]. In
our study, type of medication of diabetes was classified
to three categories; patients without medication, pa-
tients using insulin, and patients treated with oral anti-
diabetic agents. The prevalence of migraine in these
three medication groups were 23.1, 27.9, and 29.5 %,
respectively (p-value = .549).
The correlation between migraine and obesity remains
unclear, and results of various studies are inconsistent
[21]. In two population-based studies, BMI was not
correlated with the episodic migraine prevalence [27,
28]. However, two other studies indicated a positive rela-
tion between migraine and elevated BMI [29, 30]. Also,
some researchers conclude that patients with under-
weight are more likely to have an elevated risk for mi-
graine [29, 31]. In our study, no significant association
was observed between migraine and the levels of BMI
in both groups.
Our study showed that the HbA1c level is not associ-
ated with prevalence of migraine in diabetic patients. A
study on patients with both migraine and T2DM showed
that 5 patients of 36 participants lost their migraine en-
tirely or had a considerable decline in their attacks with
the onset or control of T2DM [17]. But, in other studies
on patients with migraine, no important correlations
were shown between HbA1c level and prevalence of
migraine [5].
Table 2 Association between migraine prevalence and demographic, anthropometric, and clinical characteristics in patients with
type 2 diabetes and healthy people
Variable Diabetic group Non diabetic group
n % p-value n % p-value p-value*
Sex Male 4 7.3 <.001 4 8.3 <.001 <.001
Female 37 40.2 35 34.3
Employment No 34 39.1 <.001 29 34.5 .006 <.001
Yes 7 11.7 10 15.2
Education Below diploma 32 34 .013 20 38.5 .010 .001
Diploma and upper 8 15.7 19 19.4
History of migraine in first
degree relatives
No 23 20.9 .001 17 15.6 <.001 <.001
Yes 18 50 22 53.7
Age (years) 30–35 2 15.4 14 23
36–40 8 30.8 .471 10 22.7 .251 .172
41–45 31 28.7 15 33.3
BMI (kg/m2) 20–25 9 25.7 12 22.6
25–30 19 28.4 .712 18 27.3 .492 .426
30–42 13 29.5 9 29
Medication No drug 6 23.1 …… …… …… ……
Insulin 12 27.9 .549 …… …… …… ……
Oral agants 23 29.5 …… …… …… ……
Hypoglycemia No 13 16.7 .001 …… …… …… ……
Yes 28 41.2
HbA1c (%) 5–7 11 35.5 …… …… …… ……
7–9 17 27 .306 …… …… …… ……
9–15 13 24.5 …… …… …… ……
Duration of diabetes (years) 1–5 22 25.9 …… …… …… ……
6–10 10 33.3 .031 …… …… …… ……
11–15 9 40.9 …… …… …… ……
16–20 0 …… …… …… ……
BMI indicates body mass index; HbA1c (%), percentage of blood glycosylated hemoglobin; n, the number of persons with migraine; %, frequency of migraine,
p-value*, p-value between two groups of diabetics and non-diabetics
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The cause of controversy in results regarding the associ-
ation between studied cases and migraine prevalence are
not completely explicit, but several methodological diver-
sities may underlie this difference. For example, some of
the studies used measured height and weight [29, 30, 32]
and others recorded weight and height as self-reported
[27], [28, 33, 34]. There have also been various methods
used to diagnose migraine, so creating problem in inter-
preting and comparing results across studies.
Conclusion
We observed no significant difference in the prevalence
of migraine in patients with diabetes and non-diabetic
persons. Also, among factors that were studied in dia-
betic patients, positive family history of migraine in first
degree relatives, history of hypoglycemia and T2DM
duration were significantly correlated with migraine
prevalence. Decreasing hypoglycemia among long-time
T2DM patients probably can decline migraine headache
in this group of patients.
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